GenSight Biologics S.A. (SIGHT.PA)
EUR 0.29
(-3.52%)
EUR 0.29
(-3.52%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 16.29 Million EUR | 699.9% |
| 2022 | 2.03 Million EUR | 106.42% |
| 2021 | -31.72 Million EUR | -35.03% |
| 2020 | -23.49 Million EUR | -107.85% |
| 2019 | -11.3 Million EUR | 50.43% |
| 2018 | -22.8 Million EUR | 56.5% |
| 2017 | -52.41 Million EUR | -2.65% |
| 2016 | -51.05 Million EUR | -73.45% |
| 2015 | -29.43 Million EUR | -193.29% |
| 2014 | -10.03 Million EUR | 41.28% |
| 2013 | -17.09 Million EUR | -90600.36% |
| 2012 | -18.84 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 14.3 Million EUR | 10.07% |
| 2024 Q1 | 14.3 Million EUR | -12.23% |
| 2023 Q4 | 16.29 Million EUR | -21.0% |
| 2023 FY | 16.29 Million EUR | 699.9% |
| 2023 Q3 | 20.62 Million EUR | 37.33% |
| 2023 Q1 | 19.81 Million EUR | 872.71% |
| 2023 Q2 | 15.01 Million EUR | -24.2% |
| 2022 Q2 | -13.13 Million EUR | -46.8% |
| 2022 Q3 | 6.35 Million EUR | 148.42% |
| 2022 Q1 | -8.94 Million EUR | 71.81% |
| 2022 Q4 | 2.03 Million EUR | -67.96% |
| 2022 FY | 2.03 Million EUR | 106.42% |
| 2021 Q1 | -36.01 Million EUR | -53.3% |
| 2021 Q3 | -27.51 Million EUR | 31.6% |
| 2021 Q2 | -40.23 Million EUR | -11.71% |
| 2021 FY | -31.72 Million EUR | -35.03% |
| 2021 Q4 | -31.72 Million EUR | -15.28% |
| 2020 Q3 | -19.37 Million EUR | -327.12% |
| 2020 Q2 | -4.53 Million EUR | -227.27% |
| 2020 FY | -23.49 Million EUR | -107.85% |
| 2020 Q1 | -1.38 Million EUR | 87.74% |
| 2020 Q4 | -23.49 Million EUR | -21.26% |
| 2019 Q3 | -8.98 Million EUR | 11.7% |
| 2019 Q4 | -11.3 Million EUR | -25.84% |
| 2019 FY | -11.3 Million EUR | 50.43% |
| 2019 Q1 | -7.37 Million EUR | 67.68% |
| 2019 Q2 | -10.17 Million EUR | -38.02% |
| 2018 Q3 | -22.8 Million EUR | 40.42% |
| 2018 Q4 | -22.8 Million EUR | 0.0% |
| 2018 FY | -22.8 Million EUR | 56.5% |
| 2018 Q1 | -38.26 Million EUR | 26.99% |
| 2018 Q2 | -38.26 Million EUR | 0.0% |
| 2017 Q3 | -52.41 Million EUR | 13.96% |
| 2017 Q4 | -52.41 Million EUR | 0.0% |
| 2017 Q1 | -60.91 Million EUR | -19.31% |
| 2017 Q2 | -60.91 Million EUR | 0.0% |
| 2017 FY | -52.41 Million EUR | -2.65% |
| 2016 Q1 | 30.05 Million EUR | 202.11% |
| 2016 FY | -51.05 Million EUR | -73.45% |
| 2016 Q4 | -51.05 Million EUR | 0.0% |
| 2016 Q3 | -51.06 Million EUR | 0.0% |
| 2015 Q3 | -29.43 Million EUR | -448.83% |
| 2015 Q1 | -5.36 Million EUR | 46.56% |
| 2015 FY | -29.43 Million EUR | -193.29% |
| 2015 Q2 | -5.36 Million EUR | 0.0% |
| 2015 Q4 | -29.43 Million EUR | 0.0% |
| 2014 FY | -10.03 Million EUR | 41.28% |
| 2014 Q4 | -10.03 Million EUR | 0.0% |
| 2014 Q3 | -10.03 Million EUR | 0.0% |
| 2014 Q1 | 17.09 Million EUR | 0.0% |
| 2013 FY | -17.09 Million EUR | -90600.36% |
| 2012 FY | -18.84 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 2382.073% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 108.293% |
| Adocia SA | 127 Thousand EUR | -12729.921% |
| Aelis Farma SA | -16.19 Million EUR | 200.63% |
| Biophytis S.A. | 2.7 Million EUR | -502.812% |
| Advicenne S.A. | 12.17 Million EUR | -33.832% |
| genOway Société anonyme | 2.97 Million EUR | -448.072% |
| IntegraGen SA | -709.74 Thousand EUR | 2395.741% |
| Medesis Pharma S.A. | 1.15 Million EUR | -1306.826% |
| Neovacs S.A. | -237.08 Thousand EUR | 6972.583% |
| NFL Biosciences SA | -2.27 Million EUR | 815.946% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -274.015% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 2061.837% |
| Sensorion SA | 1.37 Million EUR | -1082.248% |
| Theranexus Société Anonyme | 2.44 Million EUR | -566.652% |
| TME Pharma N.V. | -1.07 Million EUR | 1610.102% |
| Valbiotis SA | -18.13 Million EUR | 189.829% |
| TheraVet SA | 12.78 Thousand EUR | -127346.226% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -647.431% |
| argenx SE | -1.83 Billion EUR | 100.887% |
| BioSenic S.A. | 28.04 Million EUR | 41.898% |
| Celyad Oncology SA | -6.1 Million EUR | 367.027% |
| DBV Technologies S.A. | -114.95 Million USD | 114.174% |
| Galapagos NV | -157.2 Million EUR | 110.365% |
| Genfit S.A. | -7.61 Million EUR | 314.085% |
| GeNeuro SA | 5.91 Million EUR | -175.684% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 164.885% |
| Innate Pharma S.A. | -30.71 Million EUR | 153.054% |
| Inventiva S.A. | 10.48 Million EUR | -55.344% |
| MaaT Pharma SA | -10.2 Million EUR | 259.667% |
| MedinCell S.A. | 39.5 Million EUR | 58.75% |
| Nanobiotix S.A. | -24.71 Million EUR | 165.92% |
| Onward Medical N.V. | -12.89 Million EUR | 226.369% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -1039.174% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 39.939% |
| Oxurion NV | 10.71 Million EUR | -52.138% |
| Pharming Group N.V. | 99.4 Million EUR | 83.608% |
| Poxel S.A. | 44.55 Million EUR | 63.433% |
| Transgene SA | -14.4 Million EUR | 213.082% |
| Financière de Tubize SA | 78.62 Million EUR | 79.276% |
| UCB SA | 2.17 Billion EUR | 99.252% |
| Valneva SE | 82.73 Million EUR | 80.306% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 187.962% |